Bone density changes after stem cell transplant for AML
Part of Blood & lymphatic, Bones, joints & muscles, Cancer, Hormones & metabolism clinical trials.
This study looks at how a stem cell transplant for acute myeloid leukemia (AML) affects your bones over time. It measures bone density and structure to help doctors understand bone health after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML).
- You are planning to receive a stem cell transplant (allogeneic HSCT) as your first treatment.
- You have not had a prior stem cell transplant or bone marrow transplant.
- You have no other cancer that has spread to bone or was diagnosed within the past 5 years (except AML).
- You have no known bone conditions like osteoporosis, recent hip fracture, or kidney failure that could affect bone health.
- You are willing to follow study visits and use contraception if of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
This study compares two approaches for adults with high-risk acute myeloid leukemia (AML) who have had one round of chemo. One option is a stem cell transplant from a donor (using someone else's cells to rebuild your bone marrow), and the other is more chemotherapy or other treatments. The goal is to see which approach works better for people like you.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Hear when a new Myeloid Leukemia, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.